TEVA

Business Context and Reporting Period

Company: Teva Pharmaceutical Industries Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2003
Business Overview: Teva is a global pharmaceutical company and one of the world's largest generic drug manufacturers. Its operations are divided into two primary segments: Pharmaceuticals (finished dosage forms) and Active Pharmaceutical Ingredients (API). The company operates in North America, Europe, Israel, and other international markets. A significant portion of revenue (63%) is generated in North America.

Key Financial Metrics (Year Ended Dec 31, 2003)

Note: Total Debt includes $644.2M short-term and $815.4M long-term debt as of Dec 31, 2003.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 30.1% to $3.28 billion, driven by organic growth in generic pharmaceuticals, the launch of new products (e.g., generic Remeron, Vicoprofen), and a 20% revaluation of the Euro against the US dollar.
• Profitability Surge: Net income rose 68.4% to $691 million. This was significantly boosted by a one-time $100 million gain from a litigation settlement with GlaxoSmithKline (GSK) regarding Purinethol rights.
• Normalized Performance: Excluding one-time items, operating income increased 49.8% and net income increased 50.6% compared to 2002.
• Debt Reduction: Financial expenses dropped 80% to $5 million due to the conversion of $550 million in 1.5% convertible debentures into equity and the issuance of low-interest debentures (0.375%).
• Margin Expansion: Gross margin improved to 46.4% from 43.5%, attributed to a better product mix, vertical integration benefits from the API division, and favorable currency fluctuations.

Guidance, Outlook, and Risks

Outlook and Strategic Moves

• Sicor Acquisition: Teva completed the acquisition of Sicor Inc. on January 22, 2004, for approximately $3.46 billion. This transaction adds a significant injectables business and biogenerics capabilities. Results will be consolidated starting Q1 2004. Management expects the acquisition to be accretive to earnings per ADR within 12 months.
• R&D Pipeline: As of February 2004, Teva had 94 ANDAs pending FDA approval in the US, with a potential branded market value exceeding $66 billion. The company also submitted a New Drug Application (NDA) for Rasagiline (Parkinson's disease) in September 2003.
• Copaxone: The leading proprietary product for multiple sclerosis saw global sales of $720 million in 2003 (up 34%). Orphan drug exclusivity in the US expired in December 2003, though no generic ANDAs were known to be filed at the time of the report.

Risks and Contingencies

• Patent Litigation: Teva faces ongoing patent challenges, including a trade secret misappropriation claim by GSK regarding amoxiclav and a remanded appeal regarding Moexipril. The company sells some products "at risk" pending litigation outcomes.
• Regulatory Environment: Changes in the Hatch-Waxman Act and Medicare Prescription Drug Act could impact 180-day exclusivity periods. Price erosion in European markets (e.g., Netherlands, UK) remains a concern.
• Integration Risk: Successful integration of Sicor's operations is critical to realizing projected synergies. Failure to integrate could adversely affect results.
• Geopolitical Risk: Significant operations in Israel expose the company to risks related to regional hostilities and terrorism, though the company maintains contingency plans.

Investor Verification Checklist

• Sicor Integration: Verify the timeline and financial impact of the Sicor acquisition in Q1 2004 results, specifically regarding the expected one-time write-off of in-process R&D.
• One-Time Items: Confirm the sustainability of earnings by analyzing results excluding the $100 million GSK settlement gain and restructuring charges.
• Currency Exposure: Assess the impact of the strong Euro on future margins, as higher European costs in dollar terms may offset revenue benefits.
• Patent Litigation Status: Monitor the status of the GSK trade secret claim and the Moexipril appeal, as adverse rulings could result in significant damages or injunctions.
• Convertible Debt: Review the terms of the new $1.1 billion convertible debentures issued for the Sicor deal and the potential for future dilution if share prices exceed conversion thresholds.